Ionis Pharmaceuticals (IONS) stock price, revenue, and financials

Ionis Pharmaceuticals market cap is $5.1 b, and annual revenue was $729.26 m in FY 2020

$5.1 B

IONS Mkt cap, 09-Sept-2021

$111.6 M

Ionis Pharmaceuticals Revenue Q1, 2021
Ionis Pharmaceuticals Gross profit (Q1, 2021)109 M
Ionis Pharmaceuticals Gross profit margin (Q1, 2021), %97.7%
Ionis Pharmaceuticals Net income (Q1, 2021)-89.9 M
Ionis Pharmaceuticals EBIT (Q1, 2021)-92 M
Ionis Pharmaceuticals Cash, 31-Mar-2021414.2 M
Ionis Pharmaceuticals EV4.8 B
Get notified regarding key financial metrics and revenue changes at Ionis PharmaceuticalsLearn more
Banner background

Ionis Pharmaceuticals Revenue

Ionis Pharmaceuticals revenue was $729.26 m in FY, 2020 which is a 35% year over year decrease from the previous period.

Embed Graph

Ionis Pharmaceuticals Revenue Breakdown

Embed Graph

Ionis Pharmaceuticals revenue breakdown by business segment: 80.4% from Ionis Core and 19.6% from Akcea Therapeutics

Ionis Pharmaceuticals Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

599.7m1.1b729.3m

Revenue growth, %

87%(35%)

Cost of goods sold

1.8m4.4m11.9m

Gross profit

597.9m1.1b717.3m

Gross profit Margin, %

100%100%98%

R&D expense

414.6m465.7m535.1m

General and administrative expense

244.6m286.6m354.3m

Operating expense total

659.2m752.3m889.4m

EBIT

(61.4m)365.9m(172.1m)

EBIT margin, %

(10%)33%(24%)

Interest expense

44.8m48.8m45.0m

Investment income

30.2m52.2m30.6m

Pre tax profit

(76.2m)346.8m(170.0m)

Income tax expense

(291.1m)43.5m316.7m

Net Income

273.7m303.3m(486.8m)

EPS

2.12.1(3.2)

Ionis Pharmaceuticals Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

278.8m683.3m397.7m

Accounts Receivable

12.8m63.0m76.2m

Inventories

8.6m18.2m22.0m

Current Assets

2.2b2.7b2.1b

PP&E

132.2m153.7m181.1m

Total Assets

2.7b3.2b2.4b

Accounts Payable

28.7m16.1m17.2m

Short-term debt

13.7m2.0m300.5m

Current Liabilities

280.3m273.0m583.3m

Long-term debt

633.0m75.5m83.4m

Total Debt

646.7m77.5m383.9m

Total Liabilities

1.5b1.5b1.5b

Common Stock

138.0k140.0k140.0k

Additional Paid-in Capital

2.0b2.2b2.1b

Retained Earnings

(967.3m)(707.5m)(1.2b)

Total Equity

1.2b1.7b843.3m

Debt to Equity Ratio

0.5 x0 x0.5 x

Debt to Assets Ratio

0.2 x0 x0.2 x

Financial Leverage

2.2 x1.9 x2.8 x

Ionis Pharmaceuticals Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

215.0m303.3m(486.8m)

Depreciation and Amortization

12.5m16.0m17.2m

Inventories

1.4m(5.4m)(1.3m)

Accounts Payable

(655.0k)(16.3m)(2.8m)

Cash From Operating Activities

602.9m345.7m35.9m

Purchases of PP&E

(13.6m)(30.9m)(35.1m)

Cash From Investing Activities

(929.6m)(41.3m)274.5m

Long-term Borrowings

(12.5m)

Cash From Financing Activities

475.9m100.0m(596.6m)

Net Change in Cash

149.2m404.5m(285.6m)

Interest Paid

9.6m9.9m6.2m

Income Taxes Paid

9.0m25.9m

Quarterly

Ionis Pharmaceuticals Ratios

USDFY, 2018

EV/EBIT

-127.2 x

EV/CFO

12.9 x

Revenue/Employee

1.1m

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.2 x

P/E Ratio

26.1

Ionis Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020Jun, 2021

Manufacturing Facility Space, sq. ft.

28.7 k28.7 k26.8 k

Patent Applications (US)

228

Patents (US)

161

Phase I Trials Products

746

Phase II Trials Products

141724

Phase III Trials Products

356